Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)
Completed · Phase 2
Conditions studied: Relapsed/Refractory Mantle Cell Lymphoma
In brief
The goal of this clinical study is to test how well the study drug, brexucabtagene autoleucel (KTE-X19), works in participants with relapsed/refractory (r/r) mantle cell lymphoma (MCL).
Key facts
- Study ID
- NCT04880434
- Run by
- Kite, A Gilead Company
- People needed
- 95
- Starts
- 2021-04-27
- Expected to finish
- 2025-06-17
- Last updated by the study team
- 2025-11-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Banner MD Anderson Cancer Center — Gilbert, Arizona, United States
- Stanford University — Palo Alto, California, United States
- University California Los Angeles (UCLA) — Santa Monica, California, United States
- Sarah Cannon- Denver — Denver, Colorado, United States
- University of Miami — Miami, Florida, United States
- Moffitt Cancer Center — Tampa, Florida, United States
- Emory University — Atlanta, Georgia, United States
- University of Chicago — Chicago, Illinois, United States
- Loyola University Medical Center — Maywood, Illinois, United States
- Advocate Aurora Health - Advocate Lutheran General Hospital — Park Ridge, Illinois, United States
- Dana Farber Cancer Institute — Boston, Massachusetts, United States
- Karmanos Cancer Institute — Detroit, Michigan, United States
- Hackensack University Medical Center — Hackensack, New Jersey, United States
- University of Rochester — Rochester, New York, United States
- Duke University — Durham, North Carolina, United States
- Cleveland Clinic - Taussig Cancer Institute — Cleveland, Ohio, United States
- Ohio State University — Columbus, Ohio, United States
- Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
- Sarah Cannon - Tenessee — Nashville, Tennessee, United States
- Vanderbilt University — Nashville, Tennessee, United States
- Baylor Cancer Hospital — Dallas, Texas, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- Swedish Cancer Institute — Seattle, Washington, United States
- CHU de Montpellier — Montpellier, France
- Hospital Saint Louis — Paris, France
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.